AMGEN INC ($NASDAQ:AMGN) reported total revenue of USD 7.0 billion and net income of USD 1.4 billion for the second quarter of FY2023 on June 30th, 2023, representing year-over-year increases of 6.1% and 4.5%, respectively.
GoodWhale conducted an analysis of AMGEN INC‘s wellbeing and determined that the company is considered a medium risk investment. This assessment was made by taking into account both the financial and business aspects. GoodWhale also detected 2 risk warnings in AMGEN INC’s income sheet and balance sheet. To learn more about these warnings, users must register with GoodWhale. AMGEN INC is a well-established company that has been a major player in the biotechnology sector for many years. Despite its successful track record, investors should be aware of potential risks associated with the company and exercise caution when considering an investment. GoodWhale’s analysis provides an objective assessment of AMGEN INC’s health and should help investors make an informed decision. More…
Risk Rating Analysis
Star Chart Analysis
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Amgen Inc. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Amgen Inc. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Amgen Inc. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Amgen Inc are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
The competition between Amgen Inc and its competitors is fierce. Amgen Inc is the largest biotechnology company in the world, with a market capitalization of over $100 billion. Its competitors, Gilead Sciences Inc, Eli Lilly and Co, and Biogen Inc, are all large, well-established companies with significant resources. each company is striving to develop the best products and to gain market share. The competition is intense, and each company is working hard to win.
Gilead Sciences Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of drugs. The company was founded in 1987 and is headquartered in Foster City, California. Gilead Sciences Inc has a market cap of 83.2B as of 2022, a Return on Equity of 24.03%. The company’s key products include HIV/AIDS treatment, hepatitis C treatment, and oncology products. Gilead Sciences Inc also has a pipeline of products in development for various indications, including HIV, hepatitis B, non-alcoholic steatohepatitis, and respiratory syncytial virus.
– Eli Lilly and Co ($NYSE:LLY)
Eli Lilly and Co is a pharmaceutical company headquartered in Indianapolis, Indiana. The company was founded in 1876 by Colonel Eli Lilly. The company develops and markets products in the areas of diabetes, oncology, immunology, neuroscience, and other areas. Lilly has operations in more than 60 countries and sells products in more than 125 countries. Lilly has been one of the world’s leading innovators in the pharmaceutical industry, with products such as Prozac, Zyprexa, and Cialis. The company has a market cap of 316.18B as of 2022 and a Return on Equity of 45.88%.
Biogen Inc. is a global biotechnology company. The company is engaged in the discovery, development, manufacturing and commercialization of therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune diseases. Biogen has a market cap of $39.12B as of 2022 and a return on equity of 14.98%. The company’s products include aducanumab, a monoclonal antibody for the treatment of Alzheimer’s disease; SPINRAZA, a therapeutic agent for the treatment of spinal muscular atrophy; and TYSABRI, a monoclonal antibody for the treatment of multiple sclerosis.
AMGEN INC had a strong second quarter for FY2023, with total revenue of USD 7.0 billion, a 6.1% year-over-year increase. Net income also grew 4.5% year-over-year to USD 1.4 billion. Investors will likely be encouraged by the company’s continued growth and stability in spite of challenging market conditions. The company is well-positioned to continue to deliver strong results in the future, and could be a good option for long-term investors looking for a steady return.